Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a fold » _ fold (Expand Search), 5 fold (Expand Search), 2 fold (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a fold » _ fold (Expand Search), 5 fold (Expand Search), 2 fold (Expand Search)
-
901
-
902
-
903
-
904
-
905
-
906
-
907
-
908
-
909
The <i>rcan-1</i> rearrangement allele decreases expression of <i>rcan-1</i>.
Published 2020“…Cyan: p<0.01, log<sub>2</sub>(Fold Change) < -1. (The list of differential expressed genes with significance are available in <b><a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008606#pgen.1008606.s018" target="_blank">S5 Table</a></b>). …”
-
910
-
911
Positive modulation of mGluR5 decreases spine density in the nucleus accumbens but not in the dorsal striatum.
Published 2016“…<p>(A) Twenty-four hours after systemic administration, CDPPB (5–10 mg/kg, <i>n</i> = 18 animals) decreased dendritic spine density and frequency of small head diameter spines (0.2 μm bin) compared to vehicle control (<i>n</i> = 8) in the nucleus accumbens core. …”
-
912
-
913
-
914
-
915
-
916
-
917
Discovery and Hit-to-Lead Optimization of Benzothiazole Scaffold-Based DNA Gyrase Inhibitors with Potent Activity against Acinetobacter baumannii and Pseudomonas aeruginosa
Published 2023“…Starting from DNA gyrase inhibitor <b>1</b>, we identified compound <b>27</b>, featuring a 10-fold improved aqueous solubility, a 10-fold improved inhibition of topoisomerase IV from A. baumannii and P. aeruginosa, a 10-fold decreased inhibition of human topoisomerase IIα, and no cross-resistance to novobiocin. …”
-
918
Trial Sequential Analysis, parallel group trials, decreased appetite, nausea, vomiting, and abdominal pain.
Published 2017“…Therefore, based on the assumed intervention effect of RRR of 10%, an alpha of 5%, and a beta of 20% we may still need more evidence on this adverse event.…”
-
919
-
920